The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Fc Fusion Therapeutics Market by Target Indications (Neutropenia, Graft Versus Host Disease, Breast Cancer, Rheumatoid Arthritis, Non-Small Cell Lung Cancer, Neovascular Age-related Macular Degeneration, Hemophilia A and Others), Type of Fusion Molecule (Antibody, Cytokine, Growth Factor, Receptor ECD and Others), Route of Administration (Subcutaneous, Intravenous and Intravitreal) and Key Geographical Regions: Industry Trends and Global Forecasts, 2021-2030

  • Lowest Price Guaranteed From USD 5,899

  • Published
    September 2021

  • Pages
    150

  • View Count
    241

Example Insights

Fc-Fusion-Therapeutics-Market-Context Fc-Fusion-Therapeutics-Market-Potential-Benefits Fc-Fusion-Therapeutics-Market-Different-Stages-of-Development Fc-Fusion-Therapeutics-Market-Geographical-Distribution
Fc-Fusion-Therapeutics-Market-Grant-Analysis Fc-Fusion-Therapeutics-Market-Patent-Analysis Fc-Fusion-Therapeutics-Market-Publication-Analysis Fc-Fusion-Therapeutics-Market-Case-Study
Fc-Fusion-Therapeutics-Market-Future-Opportunity Fc-Fusion-Therapeutics-Market-Opportunity    

Overview

Since the approval of Enbrel®, a recombinant human tumor necrosis factor (TNF) receptor-Fc fusion protein (for the treatment of rheumatoid arthritis) in 1998, Fc fusion therapies have evolved into a prominent class of therapeutics. Currently, 13 Fc fusion drugs are commercially available, while around 50 molecules are under development for various disease indications. Some of the Fc fusion therapeutics including  Arcalyst® (recurrent pericarditis, March 2021), Reblozyl® (beta-thalassemia, September 2020) and Eylea® (diabetic retinopathy, May 2019) were approved recently. These molecules combine the beneficial pharmacological properties of biologically active ligands with the properties of the crystallizable fragment (Fc) domain of an immunoglobulin G (IgG). It is worth highlighting that these advanced variants of immunoglobulin derived therapeutic candidates are protected from lysosomal degradation once they are taken up by endothelial cells and later released back into the bloodstream by binding of the Fc-fragment to FcRn receptors present in endosomes. This prolongs the exposure of the pharmacologically active moieties to the target tissue thereby, increasing their therapeutic efficacy. Given their ability to extend the serum half-life of biologically active proteins, these disease-modifying interventions find applications across different therapeutic areas (including but not limited to oncological disorders, neurological disorders, respiratory disorders, rare genetic disorders)

Presently, several drug developers are actively engaged in the development of novel Fc fusion therapies with enhanced efficacy. The research in this field is focused on improving the stability and solubility of pharmacologically active moiety, thereby, improving its therapeutic potential. Further, several big pharma players have demonstrated interest in Fc fusion therapeutics and are investing both time and capital in this domain. The activity in this segment of the industry has also attracted the attention of both private and public sector investors / investment funds, which have extended financial support to the initiatives of capable developer companies. Moreover, the market has witnessed substantial partnership activity over the last few years. Given the ongoing efforts and the encouraging clinical trial results, the Fc fusion therapies market is poised to witness healthy growth as more drug candidates get approved and marketed over the coming decade.

Scope of the Report

The “Fc Fusion Therapeutics Market by Target Indications (Neutropenia, Graft Versus Host Disease, Breast Cancer, Rheumatoid Arthritis, Non-Small Cell Lung Cancer, Neovascular (Wet) Age-related Macular Degeneration (AMD), Hemophilia A, Neuromyelitis Optica Spectrum Disorders and Systemic Lupus Erythematosus), Type of Fusion Molecule (Antibody, Cytokine, Growth Factor, Receptor ECD and Others), Route of Administration (Subcutaneous, Intravenous and Intravitreal) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2021-2030” report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapies till 2030. The study underlines an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. Amongst other elements, the report includes:

  • A detailed assessment of the current market landscape of Fc fusion therapeutics, providing information on phase of development (marketed, clinical and pre-clinical) of lead candidates, type of fusion molecule (antibody based, cytokine based, enzyme based, growth factor based, peptide based, receptor ECD based and others), target gene, therapeutic area(s), target disease indication(s), type of therapy (combination therapy and monotherapy), route of administration (intravenous, intravitreal, oral and subcutaneous) and dosing frequency. In addition, the chapter includes information on the drug developer(s), highlighting their year of establishment, company size, and location of headquarters.
  • Elaborate profiles of key players involved in the development of Fc fusion therapeutics. Each profile features a brief overview of the company, its financial information (if available), information on product portfolio, recent developments and an informed future outlook.
  • An in-depth analysis of completed, ongoing and planned clinical studies of various Fc fusion therapeutics, based on several relevant parameters, such as trial registration year, trial phase, study design, type of masking, type of intervention model, emerging focus area, leading industry sponsors / collaborators (in terms of number of trials conducted), popular indications, popular interventions and regional distribution of trials.
  • A study of the various grants that have been awarded to research institutes engaged in conducting projects related to Fc fusion therapeutics, between 2010 and 2021 (till May), including analyses based on several relevant parameters, such as year of grant award, amount awarded, administering institute center, support period, type of grant application, purpose of grant award, activity code and emerging focus areas. In addition, it highlights the popular NIH departments, prominent program officers, and popular recipient organizations (in terms of number of grants awarded).  
  • A detailed review of close to 1,135 peer-reviewed, scientific articles related to Fc fusion therapeutics, which have been published between 2010 and 2021 (till August). It discusses the trends across parameters, such as year of publication, emerging focus areas, target therapeutic area, leading authors, and key journals (in terms of number of articles published in this domain).
  • An in-depth analysis of the patents that have been filed / granted related to Fc fusion therapeutics, since 2018. It includes information on various parameters, such as patent publication year, type of patent, geographical location / patent jurisdiction, patent age, CPC symbols, emerging focus areas, and the leading / academic players (in terms of number of patents filed). In addition, it includes a patent benchmarking analysis and a detailed valuation analysis.
  • An analysis of the partnerships established between various stakeholders in this domain, during the period 2016-2021 (till August), covering product development and commercialization, R&D agreements, mergers / acquisitions, clinical trial agreements, and other relevant types of deals. 
  • A case study on the Fc protein engineered and glycoengineered antibodies that are either marketed or being developed based on multiple of relevant parameters, such as phase of development, target disease indication, therapeutic area, type of Fc engineering, impact of Fc engineering, route of administration, and type of therapy. It also highlights the players involved in the development of these Fc protein and glycoengineered antibodies.

One of the key objectives of the report was to estimate the existing market size and the future growth opportunities for Fc fusion therapeutics, over the next few years. Based on multiple parameters, such as target patient population, likely adoption rate and the annual treatment cost, we have provided informed estimates on the evolution of the market for the period 2021-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] target indications (neutropenia, graft versus host disease, breast cancer, rheumatoid arthritis, non-small cell lung cancer, neovascular (wet) age-related macular degeneration (AMD), hemophilia A, neuromyelitis optica spectrum disorders and Systemic lupus erythematosus) [B] type of fusion molecule (antibody, cytokine, growth factor, receptor ECD and others) [C] route of administration (subcutaneous, intravenous and intravitreal) and [D] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in the report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading industry players involved in the development of Fc fusion therapeutics?
  • Which geographies are the most active in conducting clinical trials on Fc fusion therapeutics?
  • Which are the leading funding organizations providing grants for Fc fusion therapeutics?
  • Which partnership models are commonly adopted by industry stakeholders in the development of Fc fusion therapeutics? 
  • How is the current and future market opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the Fc fusion therapeutics market and its likely evolution in the short-mid term and long term.

Chapter 3 provides a general introduction to Fc fusion therapeutics, components of Fc fusion along with their mechanism of action and types. Additionally, it also highlights the applications of Fc fusion therapeutics, laying emphasis on the emerging trends and how this field of research is likely to evolve over the coming decade.

Chapter 4 includes information on over 110 programs for Fc fusion therapeutics that are either approved or being developed across different stages (commercial, clinical, and preclinical) for the treatment of various indications. It features a comprehensive analysis of pipeline molecules, highlighting the phase of development (marketed, clinical and pre-clinical) of lead candidates, type of fusion molecule (antibody based, cytokine based, enzyme based, growth factor based, peptide based, Receptor ECD based and others), target gene, therapeutic area(s), target disease indication(s), type of therapy (combination therapy and monotherapy), route of administration (intravenous, intravitreal, oral and subcutaneous) and dosing frequency. In addition, the chapter includes information on drug developer(s), highlighting their year of their establishment, company size, and location of headquarters.

Chapter 5 provides detailed profiles of the stakeholders involved in the development of Fc fusion therapeutics. Each profile features a brief overview of the company, its financial information (if available), details on its product portfolio, and recent developments and an informed future outlook.

Chapter 6 provides a detailed analysis of completed, ongoing and planned clinical studies of various Fc fusion therapeutics, based on several relevant parameters, such as trial registration year, trial phase, study design, type of masking, type of intervention model, emerging focus area, leading industry sponsors / collaborators (in terms of number of trials conducted), popular indications, popular interventions and regional distribution of trials.

Chapter 7 provides an analysis of more than 200 grants that have been awarded to research institutes engaged in projects related to Fc fusion therapeutics, between 2010 and 2021 (till May), on the basis of important parameters, such as year of grant award, amount awarded, administering institute center, support period, type of grant application, purpose of grant award, activity code and emerging focus areas. In addition, it highlights the popular NIH departments, prominent program officers, and popular recipient organizations (in terms of number of grants awarded).  

Chapter 8 provides a detailed analysis of over 1,100 research articles related to Fc fusion therapeutics, published between 2010 and 2021 (till August). The analysis takes into consideration several parameters, such as year of publication, emerging focus areas, target therapeutic area, leading authors, and key journals (in terms of number of articles published in this domain)

Chapter 9 provides an overview of the various patents that have been filed / granted related to Fc fusion therapeutics, since 2018. It includes information on various parameters, such as patent publication year, type of patent, geographical location / patent jurisdiction, patent age, CPC symbols, emerging focus areas, and the leading / academic players (in terms of number of patents filed). In addition, it includes a patent benchmarking analysis and a detailed valuation analysis.

Chapter 10 features an analysis of the various collaborations and partnerships that have been established amongst various stakeholders in this domain. It includes information on various parameters, such as year of partnerships, type of partnerships, leading players (in terms of collaborations inked) and regional distribution. We have discussed different partnership models (including product development and commercialization, R&D agreements, mergers / acquisitions and clinical trial agreements) that have been established till 2021 (till August).

Chapter 11 features a detailed market forecast analysis, highlighting the likely growth of Fc fusion therapeutics till the year 2030. We have provided inputs on the likely distribution of the market opportunity based on different target indications (neutropenia, graft versus host disease, breast cancer, rheumatoid arthritis, non-small cell lung cancer, neovascular (wet) age-related macular degeneration (AMD), hemophilia A, neuromyelitis optica spectrum disorders and systemic lupus erythematosus), type of fusion molecule (antibody, cytokine, growth factor, receptor ECD and others), route of administration (subcutaneous, intravenous and intravitreal) and key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.  

Chapter 12 features a case study on the Fc protein engineered and glycoengineered antibodies that are either marketed or being developed based on multiple of relevant parameters, such as phase of development, target disease indication, therapeutic area, type of Fc engineering, impact of Fc engineering, route of administration, and type of therapy. It also provides details on the players involved in the development of these Fc protein and glycoengineered antibodies

Chapter 13 is a summary of the overall report, presenting the insights on the contemporary market trends and the likely evolution of the Fc fusion therapeutics market. 

Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 15 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Overview of Fc Fusion Therapeutics
3.2. Components of Fc Fusion Therapeutics
3.3. Mechanism of Action
3.4. Types of Fc Fusion Therapeutics
3.4.1. Antibody-based Fc Fusion Therapeutics
3.4.2. Cytokine-based Fc Fusion Therapeutics
3.4.3. Enzyme-based Fc Fusion Therapeutics
3.4.4. Peptide-based Fc Fusion Therapeutics
3.4.5. Receptor ECD-based Fc Fusion Therapeutics

3.5. Applications of Fc Fusion Therapeutics
3.6. Advantages of Fc Fusion Therapeutics over Other Biological Moieties
3.7. Future Perspectives

4. PIPELINE REVIEW: MARKETED AND CLINICAL DRUGS
4.1. Analysis Methodology and Key Parameters
4.2. Fc Fusion Therapeutics: Drug Pipeline
4.3. Fc Fusion Therapeutics: Pipeline Analysis
4.3.1. Analysis by Phase of Development
4.3.2. Analysis by Type of Fusion Molecule
4.3.3. Analysis by Target Gene
4.3.4. Analysis by Therapeutic Area(s)
4.3.5. Analysis by Target Disease Indication(s)
4.3.6. Analysis by Type of Therapy
4.3.7. Analysis by Route of Administration 
4.3.8. Analysis by Dosing Frequency

4.4. Fc Fusion Therapeutics: List of Drug Developers
4.4.1. Analysis by Year of Establishment 
4.4.2. Analysis by Company Size
4.4.3. Analysis by Location of Headquarters
4.4.4. Leading Developers
4.4.5. Grid Analysis: Distribution by Phase of Development, Company Size and Location of Headquarters

5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Alphamab Oncology
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Product Portfolio
5.2.4. Recent Developments and Future Outlook

5.3. Amgen
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. Product Portfolio
5.3.4. Recent Developments and Future Outlook

5.4. Acceleron Pharmaceuticals
5.4.1. Company Overview
5.4.2. Financial Information
5.4.3. Product Portfolio
5.4.4. Recent Developments and Future Outlook

5.5. Bristol Myers Squibb
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. Product Portfolio
5.5.4. Recent Developments and Future Outlook

5.6. Sanofi
5.6.1. Company Overview
5.6.2. Financial Information
5.6.3. Product Portfolio
5.6.4. Recent Developments and Future Outlook

6. CLINICAL TRIAL ANALYSIS
6.1. Analysis Methodology and Key Parameters 
6.2. Fc Fusion Therapeutics: List of Clinical Trials
6.3.1. Analysis by Trial Registration Year
6.3.4. Analysis by Trial Phase
6.3.3. Analysis by Study Design
6.3.2. Analysis by Type of Masking
6.3.3. Analysis by Type of Intervention Model
6.3.9. World Cloud: Emerging Focus Areas
6.3.8. Analysis by Trial Registration Year and Geography
6.3.5. Analysis by Type of Sponsor
6.3.6. Leading Industry Players: Analysis by Number of Trials Registered
6.3.7. Leading Non-Industry Players: Analysis by Number of Trials Registered
6.3.10. Popular Indications: Analysis by Number of Registered Trials
6.3.11. Popular Interventions: Analysis by Number of Registered Trials
6.3.12. Geographical Analysis by Number of Registered Trials
6.3.13. Geographical Analysis by Number of Patients Enrolled

7. ACADEMIC GRANT ANALYSIS
7.1. Analysis Methodology and Key Parameters
7.2. Fc Fusion Therapeutics: Analysis of Academic Grants
7.2.1. Analysis by Year of Grant Award 
7.2.2. Analysis by Amount Awarded
7.2.3. Analysis by Administering Institute Center
7.2.4. Analysis by Support Period
7.2.5. Analysis by Type of Grant Application
7.2.6. Analysis by Purpose of Grant Award
7.2.7. Analysis by Activity Code
7.2.8. Word Cloud Analysis: Emerging Focus Areas
7.2.9. Popular NIH Departments: Analysis by Number of Grants
7.2.10. Prominent Program Officers: Analysis by Number of Grants
7.2.11. Popular Recipient Organizations: Analysis by Number of Grants

8. PUBLICATION ANALYSIS
8.1. Analysis Methodology and Key Parameters 
8.2. Fc Fusion Therapeutics: Recent Publications
8.3. Analysis by Year of Publication
8.4. Word Cloud Analysis: Emerging Focus Areas
8.5. Analysis by Target Therapeutic Area
8.6. Leading Authors: Analysis by Number of Publications
8.7. Key Journals: Analysis by Number of Publications

9. PATENT ANALYSIS
9.1. Analysis Methodology and Key Parameters
9.2. Fc Fusion Therapeutics: Patent Analysis
9.2.1. Analysis by Publication Year
9.2.2. Analysis by Type of Patent
9.2.3. Analysis by Geographical Location
9.2.4. Analysis by Patent Age
9.2.5. Analysis by CPC Symbols
9.2.6. Word Cloud Analysis: Emerging Focus Areas
9.2.7. Leading Patent Assignees: Analysis by Number of Patents
9.2.8. Leading Industry Players: Analysis by Number of Patents
9.2.9. Leading Non-Industry Players: Analysis by Number of Patents
9.2.10. Fc Fusion Therapeutics: Patent Benchmarking Analysis
9.2.10. Fc Fusion Therapeutics: Patent Valuation Analysis

10. PARTNERSHIPS AND COLLABORATIONS
10.1. Analysis Methodology and Key Parameters
10.2. Partnership Models
10.3. Fc Fusion Therapeutics: List of Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Type of Partnership and Type of Fusion molecule
10.3.4. Analysis by Year of Partnership and Type of Partner
10.3.5. Analysis by Type of Partnership and Type of Partner
10.3.6. Most Active Players: Analysis by Number of Partnerships 
10.3.7. Regional Analysis 
10.3.7.1. Intercontinental and Intracontinental Agreements

11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Forecast Methodology and Key Assumptions
11.2. Global Fc Fusion Therapeutics Market, 2021-2031
11.3. Global Fc Fusion Therapeutics Market, 2021-2031: Distribution by Target Indication
11.4. Global Fc Fusion Therapeutics Market, 2021-2031: Distribution by Type of Fusion Molecule
11.5. Global Fc Fusion Therapeutics Market, 2021-2031: Distribution by Type of Therapy
11.6. Global Fc Fusion Therapeutics Market, 2021-2031: Distribution by Route of Administration
11.7. Global Fc Fusion Therapeutics Market, 2021-2031: Distribution by Geography

11.8. Fc Fusion Therapeutics: Individual Product Sales Forecasts 
11.8.1. ABP 938 (Amgen)
11.8.2. Alprolix® (Sanofi)
11.8.3. AnBaiNuo® (Hisun Pharmaceuticals)
11.8.4. Arcalyst® (Kiniska Pharmaceuticals)
11.8.5. BIVV001 (Sanofi)
11.8.6. CD24Fc (Merck)
11.8.7. Eloctate® (Biogen)
11.8.8. Eylea™ (Regeneron Pharmaceuticals)
11.8.9. FRSW107 (Zhengzhou Gensciences)
11.8.10. KN035 (Alphamab Oncology)
11.8.11. KN046 (Alphamab Oncology)
11.8.12. Lumitin® (Chengdu Kanghong Biotech)
11.8.13. Reblozyl® (Bristol-Myers Squibb)
11.8.14. RyzneutaTM (Evive Biotech)
11.8.15. Strensiq® (AstraZeneca)
11.8.16. Telitacicept (RemeGen)

12. CASE STUDY: FC PROTEIN ENGINEERED AND GLYCOENGINEERED ANTIBODIES
12.1. Fc Protein Engineered and Glycoengineered Antibodies: Drug Pipeline
12.1.1. Analysis by Phase of Development 
12.1.2. Analysis by Target Disease Indication
12.1.3. Analysis by Therapeutic Area
12.1.4. Analysis by Type of Fc Engineering
12.1.5. Analysis by Impact of Fc Engineering
12.1.6. Analysis by Route of Administration
12.1.7. Analysis by Type of Therapy

12.2. Fc Protein Engineered and Glycoengineered Antibodies: List of Developers
12.2.1 Analysis by Year of Establishment
12.2.2 Analysis by Company Size
12.2.3 Analysis by Location of Headquarters

13. CONCLUSION

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Overall Market Landscape
Figure 2.2 Executive Summary: Clinical Trial Analysis
Figure 2.3 Executive Summary: Academic Grant Analysis
Figure 2.4 Executive Summary: Publication Analysis
Figure 2.5 Executive Summary: Patent Analysis
Figure 2.6 Executive Summary: Partnerships and Collaborations
Figure 2.7 Executive Summary: Market Forecast
Figure 3.1 Components of Fc Fusion Therapeutics
Figure 3.2 Mechanism of Action
Figure 4.1 Fc Fusion Therapeutics: Distribution by Phase of Development
Figure 4.2 Fc Fusion Therapeutics: Distribution by Type of Fusion Molecule
Figure 4.3 Fc Fusion Therapeutics: Distribution by Target Gene
Figure 4.4 Fc Fusion Therapeutics: Distribution by Therapeutic Area(s)
Figure 4.5 Fc Fusion Therapeutics: Distribution by Target Disease Indication(s)
Figure 4.6 Fc Fusion Therapeutics: Distribution by Type of Therapy
Figure 4.7 Fc Fusion Therapeutics: Distribution by Route of Administration
Figure 4.8 Fc Fusion Therapeutics: Distribution by Dosing Frequency
Figure 4.9 Fc Fusion Therapeutics Developers: Distribution by Year of Establishment
Figure 4.10 Fc Fusion Therapeutics Developers: Distribution by Company Size
Figure 4.11 Fc Fusion Therapeutics Developers: Distribution by Location of Headquarters
Figure 4.12 Leading Developers: Distribution by Number of Fc Fusion Therapeutics
Figure 4.13 Grid Analysis: Distribution by Phase of Development, Company Size and Location of Headquarters
Figure 5.1 Amgen: Annual Revenues, 2016-H1 2021 (USD Billion)
Figure 5.2 Acceleron Pharmaceuticals: Annual Revenues, 2016-H1 2021 (USD Billion)
Figure 5.3 Bristol Myers Squibb: Annual Revenues, 2016-H1 2021 (USD Billion)
Figure 5.4 Sanofi: Annual Revenues, 2016-H1 2021 (USD Billion)
Figure 6.1 Clinical Trial Analysis: Distribution by Trial Registration Year
Figure 6.2 Clinical Trial Analysis: Distribution by Trial Phase
Figure 6.3 Clinical Trial Analysis: Distribution by Study Design
Figure 6.4 Clinical Trial Analysis: Distribution by Type of Masking
Figure 6.5 Clinical Trial Analysis: Distribution by Type of Intervention Model
Figure 6.6 World Cloud Analysis: Emerging Focus Areas
Figure 6.7 Clinical Trial Analysis: Distribution by Trial Registration Year and Geography
Figure 6.8 Clinical Trial Analysis: Distribution by Type of Sponsor
Figure 6.9 Leading Industry Players: Distribution by Number of Trials Registered
Figure 6.10 Leading Non-Industry Players: Distribution by Number of Trials Registered
Figure 6.11 Popular Indications: Distribution by Number of Registered Trials
Figure 6.12 Popular Interventions: Distribution by Number of Registered Trials
Figure 6.13 Popular Indications: Distribution by Number of Registered Trials
Figure 6.14 Popular Interventions: Distribution by Number of Registered Trials
Figure 6.15 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Figure 6.16 Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
Figure 7.1 Grant Analysis: Cumulative Trend by Year of Grant Award, 2010-2021
Figure 7.2 Grant Analysis: Cumulative Distribution by Amount Awarded (USD Million), 2010-2021
Figure 7.3 Grant Analysis: Distribution by Administering Institute Center
Figure 7.4 Grant Analysis: Distribution by Support Period
Figure 7.5 Grant Analysis: Distribution by Type of Grant Application
Figure 7.6 Grant Analysis: Distribution by Purpose of Grant Award
Figure 7.7 Grant Analysis: Distribution by Activity Code
Figure 7.8 Word Cloud Analysis: Emerging Focus Areas
Figure 7.9 Popular NIH Departments: Distribution by Number of Grants
Figure 7.10 Prominent Program Officers: Distribution by Number of Grants
Figure 7.11 Popular Recipient Organizations: Distribution by Number of Grants
Figure 8.1 Publication Analysis: Cumulative Year-wise Trend, 2010-2021
Figure 8.2 Word Cloud Analysis: Emerging Focus Areas
Figure 8.3 Publication Analysis: Distribution by Target Therapeutic Area
Figure 8.4 Leading Authors: Distribution by Number of Publications
Figure 8.5 Key Journals: Distribution by Number of Publications
Figure 9.1 Patent Analysis: Distribution by Publication Year
Figure 9.2 Patent Analysis: Distribution by Type of Patent
Figure 9.3 Patent Analysis: Distribution by Geographical Location
Figure 9.4 Patent Analysis: Distribution by Patent Age
Figure 9.5 Patent Analysis: Distribution by CPC Symbols
Figure 9.6 Word Cloud Analysis: Emerging Focus Areas
Figure 9.7 Leading Patent Assignees: Distribution by Number of Patents
Figure 9.8 Leading Industry Players: Distribution by Number of Patents
Figure 9.9 Leading Non-Industry Players: Distribution by Number of Patents
Figure 9.10 Patent Analysis: Distribution by Patent Benchmarking
Figure 9.11 Patent Analysis: Distribution by Patent Valuation
Figure 10.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-2021
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Fusion Molecule
Figure 10.4 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 10.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 10.6 Most Active Players: Distribution by Number of Partnerships
Figure 10.7 Partnerships and Collaborations: Regional Distribution
Figure 10.7.1 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 11.1 Global Fc Fusion Therapeutics Market, 2021-2030 (USD Million)
Figure 11.2 Global Fc Fusion Therapeutics Market, 2021-2030: Distribution by Target Indication (USD Million)
Figure 11.3 Global Fc Fusion Therapeutics Market, 2021-2030: Distribution by Type of Fusion Molecule (USD Million)
Figure 11.4 Global Fc Fusion Therapeutics Market, 2021-2030: Distribution by Type of Therapy (USD Million)
Figure 11.5 Global Fc Fusion Therapeutics Market, 2021-2030: Distribution by Route of Administration (USD Million
Figure 11.6 Global Fc Fusion Therapeutics Market, 2021-2030: Distribution by Geography (USD Million)
Figure 11.7 ABP 938: Sales Forecast, 2024-2030 (USD Million)
Figure 11.8 Alprolix®: Sales Forecast, 2021-2030 (USD Million)
Figure 11.9 AnBaiNuo®: Sales Forecast, 2021-2030 (USD Million)
Figure 11.10 Arcalyst®: Sales Forecast, 2021-2030 (USD Million)
Figure 11.11 BIVV001: Sales Forecast, 2025-2030 (USD Million)
Figure 11.12 CD24Fc: Sales Forecast, 2022-2030 (USD Million)
Figure 11.13 Eloctate®: Sales Forecast, 2021-2030 (USD Million)
Figure 11.14 Eylea™: Sales Forecast, 2021-2030 (USD Million)
Figure 11.15 FRSW107: Sales Forecast, 2024-2030 (USD Million)
Figure 11.16 KN035: Sales Forecast, 2024-2030 (USD Million)
Figure 11.17 KN046: Sales Forecast, 2025-2030 (USD Million)
Figure 11.18 Lumitin®: Sales Forecast, 2021-2030 (USD Million)
Figure 11.19 Reblozyl®: Sales Forecast, 2021-2030 (USD Million)
Figure 11.20 RyzneutaTM: Sales Forecast, 2022-2030 (USD Million)
Figure 11.21 Strensiq®: Sales Forecast, 2021-2030 (USD Million)
Figure 11.21 Telitacicept: Sales Forecast, 2024-2030 (USD Million)
Figure 12.1 Fc Protein Engineered and Glycoengineered Antibodies: Analysis by Phase of Development 
Figure 12.2 Fc Protein Engineered and Glycoengineered Antibodies: Analysis by Target Disease Indication
Figure 12.3 Fc Protein Engineered and Glycoengineered Antibodies: Analysis by Therapeutic Area
Figure 12.4 Fc Protein Engineered and Glycoengineered Antibodies: Analysis by Type of Fc Engineering
Figure 12.5 Fc Protein Engineered and Glycoengineered Antibodies: Analysis by Impact of Fc Engineering
Figure 12.6 Fc Protein Engineered and Glycoengineered Antibodies: Analysis by Route of Administration
Figure 12.7 Fc Protein Engineered and Glycoengineered Antibodies: Analysis by Type of Therapy
Figure 12.8 Fc Protein Engineered and Glycoengineered Antibodies Developers: Analysis by Year of Establishment
Figure 12.9 Fc Protein Engineered and Glycoengineered Antibodies Developers Analysis by Company Size
Figure 12.10 Fc Protein Engineered and Glycoengineered Antibodies Developers Analysis by Location of Headquarters
Figure 13.1 Concluding Remarks: Overall market Landscape
Figure 13.2 Concluding Remarks: Clinical Trial Analysis
Figure 13.3 Concluding Remarks: Academic Grants Analysis
Figure 13.4 Concluding Remarks: Publication Analysis
Figure 13.5 Concluding Remarks: Patent Analysis
Figure 13.6 Concluding Remarks: Partnerships and Collaborations
Figure 13.7 Concluding Remarks: Market Forecast

List Of Tables

Table 4.1  Fc Fusion Therapeutics: Drug Pipeline
Table 4.2  Fc Fusion Therapeutics: List of Drug Developers
Table 5.1  Fc Fusion Therapeutics: List of Companies Profiled
Table 5.2  Drug Profile: KN015
Table 5.3  Drug Profile: KN046
Table 5.4  Drug Profile: KN035
Table 5.5  Drug Profile: KN058
Table 5.6  Drug Profile: KN055
Table 5.7  Drug Profile: KN019
Table 5.8  Alphamab Oncology: Recent Developments and Future Outlook
Table 5.9  Drug Profile: AMG 386
Table 5.10  Drug Profile: AMG 592
Table 5.11  Drug Profile: ABP 938
Table 5.12  Drug Profile: Enbrel®
Table 5.13  Drug Profile: Nplate®
Table 5.14  Amgen: Recent Developments and Future Outlook
Table 5.15  Drug Profile: ACE-1334
Table 5.16  Drug Profile: ACE-011
Table 5.17  Acceleron Pharmaceuticals: Recent Developments and Future Outlook
Table 5.18  Drug Profile: AVID200
Table 5.19  Drug Profile: Orencia®
Table 5.20  Drug Profile: Nulojix®
Table 5.21  Drug Profile: REBLOZYL®
Table 5.22  Bristol-Myers Squibb: Recent Developments and Future Outlook
Table 5.23  Drug Profile: Alprolix®
Table 5.24  Drug Profile: BIVV001
Table 5.25  Drug Profile: Zaltrap®
Table 5.26  Sanofi: Recent Developments and Future Outlook
Table 6.1  Fc Fusion Therapeutics: List of Clinical Trials
Table 10.1  Fc Fusion Therapeutics: List of Partnerships and Collaborations
Table 12.1  Fc Protein Engineered and Glycoengineered Antibodies: Drug Pipeline
Table 12.2  Fc Protein Engineered and Glycoengineered Antibodies: List of Drug Developers
Table 14.1  Fc Fusion Therapeutics: Distribution by Phase of Development
Table 14.2  Fc Fusion Therapeutics: Distribution by Type of Fusion Molecule
Table 14.3  Fc Fusion Therapeutics: Distribution by Target Gene
Table 14.4  Fc Fusion Therapeutics: Distribution by Therapeutic Area(s)
Table 14.5  Fc Fusion Therapeutics: Distribution by Target Disease Indication(s)
Table 14.6  Fc Fusion Therapeutics: Distribution by Type of Therapy
Table 14.7  Fc Fusion Therapeutics: Distribution by Route of Administration
Table 14.8  Fc Fusion Therapeutics: Distribution by Dosing Frequency
Table 14.9  Fc Fusion Therapeutics: Distribution by Year of Establishment
Table 14.10  Fc Fusion Therapeutics: Distribution by Company Size
Table 14.11  Fc Fusion Therapeutics: Distribution by Location of Headquarters
Table 14.12  Fc Fusion Therapeutics: Distribution by Leading Developers
Table 14.13  Amgen: Annual Revenues, 2016-H1 2021 (USD Billion)
Table 14.14  Acceleron Pharmaceuticals: Annual Revenues, 2016-H1 2021 (USD Billion)
Table 14.15  Bristol Myers Squibb: Annual Revenues, 2016-H1 2021 (USD Billion)
Table 14.16  Sanofi: Annual Revenues, 2016-H1 2021 (USD Billion)
Table 14.17  Clinical Trial Analysis: Distribution by Trial Registration Year
Table 14.18  Clinical Trial Analysis: Distribution by Trial Phase
Table 14.19  Clinical Trial Analysis: Distribution by Study Design
Table 14.20  Clinical Trial Analysis: Distribution by Type of Masking
Table 14.21  Clinical Trial Analysis: Distribution by Type of Intervention Model
Table 14.22  Clinical Trial Analysis: Distribution by Trial Registration Year and Geography
Table 14.23  Clinical Trial Analysis: Distribution by Type of Sponsor
Table 14.24  Leading Industry Players: Distribution by Number of Trials Registered
Table 14.25  Leading Non-Industry Players: Distribution by Number of Trials Registered
Table 14.26  Popular Indications: Analysis by Number of Registered Trials
Table 14.27  Popular Interventions: Analysis by Number of Registered Trials
Table 14.28  Popular Indications: Distribution by Number of Registered Trials
Table 14.29  Popular Interventions: Distribution by Number of Registered Trials
Table 14.30  Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Table 14.31  Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
Table 14.32  Grant Analysis: Cumulative Trend by Year of Grant Award, 2010-2021
Table 14.33  Grant Analysis: Cumulative Distribution by Amount Awarded (USD Million), 2010-2021
Table 14.34  Grant Analysis: Distribution by Administering Institute Center
Table 14.35  Grant Analysis: Distribution by Support Period
Table 14.36  Grant Analysis: Distribution by Type of Grant Application
Table 14.37  Grant Analysis: Distribution by Purpose of Grant Award
Table 14.38  Grant Analysis: Distribution by Activity Code
Table 14.39  Popular NIH Departments: Distribution by Number of Grants
Table 14.40  Prominent Program Officers: Distribution by Number of Grants
Table 14.41  Popular Recipient Organizations: Distribution by Number of Grants
Table 14.42  Publication Analysis: Cumulative Year-wise Trend, 2010-2021
Table 14.43  Publication Analysis: Distribution by Target Therapeutic Area
Table 14.44  Leading Authors: Distribution by Number of Publications
Table 14.45  Key Journals: Distribution by Number of Publications
Table 14.46  Patent Analysis: Distribution by Publication Year
Table 14.47  Patent Analysis: Distribution by Type of Patent
Table 14.48  Patent Analysis: Distribution by Geographical Location
Table 14.49  Patent Analysis: Distribution by Patent Age
Table 14.50  Patent Analysis: Distribution by CPC Symbols
Table 14.51  Leading Patent Assignees: Distribution by Number of Patents
Table 14.52  Leading Industry Players: Distribution by Number of Patents
Table 14.53  Patent Analysis: Distribution by Patent Benchmarking
Table 14.54  Patent Analysis: Distribution by Patent Valuation
Table 14.55  Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-2021
Table 14.56  Partnerships and Collaborations: Distribution by Type of Partnership
Table 14.57  Partnerships and Collaborations: Distribution by Type of Partnership and Type of Fusion Molecule
Table 14.58  Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 14.59  Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 14.60  Most Active Players: Distribution by Number of Partnerships
Table 14.61  Partnerships and Collaborations: Regional Distribution
Table 14.62  Global Fc Fusion Therapeutics Market, 2021-2030 (USD Million)
Table 14.63  Global Fc Fusion Therapeutics Market, 2021-2030: Distribution by Target Indication (USD Million)
Table 14.64  Global Fc Fusion Therapeutics Market, 2021-2030: Distribution by Type of Therapy (USD Million)
Table 14.65  Global Fc Fusion Therapeutics Market, 2021-2030: Distribution by Route of Administration (USD Million
Table 14.66  Global Fc Fusion Therapeutics Market, 2021-2030: Distribution by Geography (USD Million)
Table 14.67  ABP 938: Sales Forecast, 2024-2030 (USD Million)
Table 14.68  Alprolix®: Sales Forecast, 2021-2030 (USD Million)
Table 14.69  AnBaiNuo®: Sales Forecast, 2021-2030 (USD Million)
Table 14.70  Arcalyst®: Sales Forecast, 2021-2030 (USD Million)
Table 14.71  BIVV001: Sales Forecast, 2025-2030 (USD Million)
Table 14.72  CD24Fc: Sales Forecast, 2022-2030 (USD Million)
Table 14.73  Eloctate®: Sales Forecast, 2021-2030 (USD Million)
Table 14.74  Eylea™: Sales Forecast, 2021-2030 (USD Million)
Table 14.75  FRSW107: Sales Forecast, 2024-2030 (USD Million)
Table 14.76  KN035: Sales Forecast, 2024-2030 (USD Million)
Table 14.77  KN046: Sales Forecast, 2025-2030 (USD Million)
Table 14.78  Lumitin®: Sales Forecast, 2021-2030 (USD Million)
Table 14.79  Reblozyl®: Sales Forecast, 2021-2030 (USD Million)
Table 14.80  RyzneutaTM: Sales Forecast, 2022-2030 (USD Million)
Table 14.81  Strensiq®: Sales Forecast, 2021-2030 (USD Million)
Table 14.82  Telitacicept: Sales Forecast, 2024-2030 (USD Million)
Table 14.83  Fc Protein Engineered and Glycoengineered Antibodies: Analysis by Phase of Development 
Table 14.84  Fc Protein Engineered and Glycoengineered Antibodies: Analysis by Target Disease Indication
Table 14.85  Fc Protein Engineered and Glycoengineered Antibodies: Analysis by Therapeutic Area
Table 14.86  Fc Protein Engineered and Glycoengineered Antibodies: Analysis by Type of Fc Engineering
Table 14.87  Fc Protein Engineered and Glycoengineered Antibodies: Analysis by Impact of Fc Engineering
Table 14.88  Fc Protein Engineered and Glycoengineered Antibodies: Analysis by Route of Administration
Table 14.89  Fc Protein Engineered and Glycoengineered Antibodies: Analysis by Type of Therapy
Table 14.90  Fc Protein Engineered and Glycoengineered Antibodies Developers: Analysis by Year of Establishment
Table 14.91  Fc Protein Engineered and Glycoengineered Antibodies Developers Analysis by Company Size
Table 14.92  Fc Protein Engineered and Glycoengineered Antibodies Developers Analysis by Location of Headquarters

List Of Companies

The following companies and organizations have been mentioned in the report.

  1. 3SBio
  2. AbbVie
  3. Acceleron Pharma
  4. AdAlta
  5. Agenus
  6. Akeso
  7. Alexion Pharmaceuticals
  8. Alphamab Oncology
  9. Amgen
  10. Anthera Pharmaceuticals
  11. Apogenix
  12. argenx
  13. AstraZeneca
  14. Bayer
  15. BeiGene
  16. BIOCAD
  17. Biogen
  18. Boehringer Ingelheim
  19. Brigham and Women's Hospital (BWH)
  20. Bristol Myers Squibb
  21. CANbridge Pharmaceuticals
  22. Cantargia
  23. Celgene
  24. Celldex Therapeutics
  25. Chengdu Kanghong Pharmaceutical 
  26. Chia Tai Tianqing Pharmaceutical 
  27. Chiesi Farmaceutici
  28. CSL Behring
  29. Daiichi Sankyo
  30. Dana-Farber Cancer Institute
  31. Eli Lilly
  32. Evive Biotech
  33. Forbius
  34. Genentech
  35. Gilead Sciences
  36. GlaxoSmithKline
  37. Haimen Gensciences
  38. Harvard College
  39. Horizon Therapeutics
  40. Huabo Biopharm
  41. Humanigen
  42. Incyte
  43. Inhibrx
  44. National Institute of Health and Medical Research (Inserm)
  45. Jiangsu Gensciences
  46. Johnson & Johnson
  47. Junshi Biosciences
  48. KBI Biopharma
  49. Kiniksa Pharmaceuticals
  50. Kyowa Kirin
  51. LEO Pharma
  52. MacroGenics
  53. Memorial Sloan Kettering Cancer Center
  54. Menarini
  55. Merck
  56. MorphoSys
  57. National Cancer Institute (NCI)
  58. National Institute of Allergy and Infectious Diseases (NIAID)
  59. NGM Biopharmaceuticals
  60. Novartis
  61. OncoImmune (acquired by Merck)
  62. Pfizer
  63. Protalix Biotherapeutics
  64. Provention Bio
  65. Regeneron Pharmaceuticals
  66. RemeGen
  67. Resolve Therapeutics
  68. Roche
  69. Sanofi
  70. Seagen
  71. Shandong TheraWisdom Biopharma
  72. Shanghai Henlius Biotech
  73. Swedish Orphan Biovitrum (Sobi)
  74. SYNIMMUNE
  75. SystImmune
  76. Takeda Pharmaceutical 
  77. TG Therapeutics
  78. Tiziana Life Sciences
  79. United BioPharma (UBP)
  80. United States Department of Health and Human Services (HHS)
  81. University of California
  82. University of Pennsylvania
  83. USHEALTH
  84. Vir Biotechnology
  85. Visterra 
  86. Xencor
  87. Zhejiang Hisun Pharmaceutical
  88. Zhengzhou Gensciences
  89. Zymeworks

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com